artemether

artemether. It is a lipid-soluble derivative of the natural sesquiterpene lactone artemisinin, which is isolated from the plant Artemisia annua. The compound is a key component of artemisinin-based combination therapies (ACTs), which are the first-line treatment recommended by the World Health Organization for uncomplicated Plasmodium falciparum malaria. Developed in the late 20th century, it is typically administered in combination with lumefantrine to enhance efficacy and delay the development of antimalarial drug resistance.

Chemical properties

Artemether is a white, crystalline powder that is soluble in organic solvents like ethanol and dimethyl sulfoxide but practically insoluble in water. Its chemical structure features a distinctive endoperoxide bridge within a sesquiterpene lactone framework, a moiety critical for its antimalarial activity. The compound is more lipophilic than its parent compound, artemisinin, due to the replacement of a carbonyl group with a methoxy group at the C-10 position, which improves its absorption and distribution. It is sensitive to degradation by light, heat, and acidic conditions, necessitating careful formulation and storage.

Medical uses

The primary medical use of artemether is in the treatment of acute, uncomplicated malaria caused by Plasmodium falciparum, most commonly in fixed-dose combination with lumefantrine as per WHO guidelines. It is also used in combination with other antimalarials like amodiaquine or sulfadoxine/pyrimethamine in different geographical regions to combat local resistance patterns. Beyond malaria, research has explored its potential efficacy against other parasitic diseases such as schistosomiasis and certain cancers, including hepatocellular carcinoma, though these are not standard indications. Its rapid action makes it crucial in severe malaria cases, though for that indication, the water-soluble derivative artesunate is preferred for intravenous administration.

Mechanism of action

The antimalarial activity is initiated when the endoperoxide bridge within the molecule is cleaved by intraparasitic ferrous iron, which is abundant in the malaria parasite's digestive vacuole due to its digestion of hemoglobin. This cleavage generates highly reactive carbon-centered free radicals and other oxidative species that alkylate and damage critical parasite proteins and membranes. Key targets include the sarco/endoplasmic reticulum calcium ATPase (SERCA) ortholog of Plasmodium falciparum, known as PfATP6, leading to disruption of calcium homeostasis and cellular function. This rapid, iron-dependent mechanism results in the swift killing of the asexual blood stages of the parasite, providing rapid clinical relief and reducing parasite biomass.

Pharmacokinetics

Following oral administration, artemether is rapidly absorbed and undergoes extensive first-pass metabolism in the liver, primarily by the cytochrome P450 enzyme CYP3A4, to its active metabolite dihydroartemisinin. The presence of food, particularly fats, significantly enhances its bioavailability. It has a large volume of distribution, readily crossing membranes to reach infected red blood cells, and is highly bound to plasma proteins. The elimination half-life of artemether itself is short (approximately 2-3 hours), but the active metabolite dihydroartemisinin has a slightly longer half-life, though both are cleared quickly, necessitating multi-dose regimens over several days to ensure complete parasite clearance.

Adverse effects

Adverse effects are generally mild and transient, commonly including gastrointestinal disturbances such as nausea, abdominal pain, and diarrhea. Other reported effects include headache, dizziness, and pruritus. Serious adverse events are rare but can include prolongation of the QT interval on electrocardiography, particularly when used in combination with other drugs that affect cardiac repolarization. Allergic reactions, including urticaria and, in extreme cases, anaphylaxis, have been documented. Its use in the first trimester of pregnancy is generally avoided due to limited safety data, though the benefits often outweigh risks in treating severe malaria.

History and development

The development of artemether is rooted in the discovery of artemisinin in the 1970s by Chinese scientist Tu Youyou and her team, who isolated it from Artemisia annua based on traditional Chinese medicine texts. This work, part of the secret Project 523 initiated by the People's Liberation Army, earned Tu the Nobel Prize in Physiology or Medicine in 2015. To improve the solubility and stability of artemisinin, researchers at the Academy of Military Medical Sciences in Beijing and later the World Health Organization developed semi-synthetic derivatives, including artemether, in the 1980s. Its deployment globally accelerated after the spread of resistance to older drugs like chloroquine and sulfadoxine/pyrimethamine, leading to its central role in modern malaria control programs endorsed by the Roll Back Malaria Partnership. Category:Antimalarial agents Category:Ethers Category:World Health Organization essential medicines